Barclays Downgrades Vertex Pharmaceuticals to Equal-Weight, Raises Price Target to $509
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang has downgraded Vertex Pharmaceuticals (NASDAQ:VRTX) from Overweight to Equal-Weight while raising the price target from $472 to $509.
August 05, 2024 | 10:49 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Gena Wang downgraded Vertex Pharmaceuticals from Overweight to Equal-Weight, while raising the price target from $472 to $509.
The downgrade from Overweight to Equal-Weight suggests a neutral stance on the stock, which could lead to a mixed reaction in the market. However, the raised price target to $509 indicates some positive outlook, balancing the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100